Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Women.

Trial Profile

Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Women.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Efavirenz; Lamivudine; Zidovudine
  • Indications HIV infections; Malaria
  • Focus Therapeutic Use
  • Acronyms PROMOTE-PIs; PROMOTE-Pregnant Women and Infants
  • Most Recent Events

    • 10 Nov 2017 Results published in the Clinical Infectious Diseases
    • 11 Oct 2017 Results of secondary analysis assessing angiogenic factors associated with adverse birth outcomes published in the American Journal of Obstetrics and Gynecology
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top